ArticleTranslational gastroenterology and hepatology2026
Intestinal homeostasis alteration toward mucosal inflammation with blocking IL-17 in psoriasis patients: a case series.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin (IL)-17 is a key cytokine in various inflammatory disease. Targeting IL-17 signals blockage did not improve inflammatory bowel disease (IBD) clinically, but also even developed de novo enteritis in non-IBD subjects. Little is known about the effects of blocking IL-17 signaling on intestinal homeostasis. This study investigated intestinal immunity under the inhibition of IL-17 signaling. Case Description: Refractory patients with psoriasis who started receiving anti-IL-17 or anti-IL-17 receptor inhibitors were included in this case series. These patients never experienced IBDs. Evaluation for fecal immunochemistry test (FIT), fecal calprotectin (fCal), endoscopic findings, colonic mucosa histology, and fecal microbial composition before and 3 months after starting treatment on the subjects was performed. Fecal microbial composition was analyzed with 16S rRNA. We present a series of 5 cases. The median age was 64 years, the disease duration was 31 years, two were female, four received secukinumab, and one received brodalumab. The median FIT level and fCal level was 0 ng/mL [interquartile range (IQR), 19.5 ng/mL] and 39.4 mg/kg (IQR, 304 mg/kg) at baseline. Thereafter, the median FIT level and fCal level on 3 months after initiating antibody therapy increased to 19 ng/mL (IQR, 15 ng/mL) and 222 mg/kg (IQR, 71 mg/kg), respectively. Endoscopic findings before administration showed mild edema in one patient and mild redness in one patient, and thereafter these two patients showed unchanged endoscopic findings, and one patient showed new mild edema and another patient showed new mild redness after administration. The number of mononuclear cells infiltrating in the mucosa significantly increased with antibody administration. Microbial community analysis did not show alteration in alpha diversity after antibody administration. Conclusions: Although no one occurred clinical symptoms after IL-17 inhibition in this case series, blocking IL-17 signals altered intestinal homeostasis toward mucosal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.